logo
Share SHARE
FONT-SIZE Plus   Neg

Lonza, Agennix Ink Deal For Production Of Talactoferrin - Quick Facts

Lonza Group AG (LZAGF.PK) said it entered into an agreement with Agennix AG for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy, talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer.

As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. Lonza stated that the agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

Rajesh Malik, chief medical officer and Management Board member of Agennix, said, "We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
KMG Chemicals Inc. (KMG) is likely to beat earnings per share or EPS estimates, when it reports first quarter results on December 11, after the bell. First quarter results of KMG are expected to benefit from the impact of Irma and Harvey, and early October fires in the West. Sysco Corp. is looking ahead to own 50 fully electric semi tracks to be launched by Tesla. The new electric tractors could run 500 miles on a single charging. The order from the food service distribution giant that owns more than 7000 trucks is worth up to $10 million. Patreon, the crowdfunding platform for artists, announced Wednesday a change in its payment structure that it says will help creators keep more money. Meanwhile, many are concerned that the change may discourage their patrons from pledging.
comments powered by Disqus
Follow RTT